Premium
O2‐04‐04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE
Author(s) -
Weston Philip SJ.,
Poole Teresa,
Ryan Natalie S.,
Liang Yuying,
O'Connor Antoinette,
Heslegrave Amanda,
Druyeh Ronald,
Mead Simon,
Blennow Kaj,
Rossor Martin N.,
Schott Jonathan M.,
Zetterberg Henrik,
Fox Nick C.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2660
Subject(s) - asymptomatic , asymptomatic carrier , medicine , psen1 , neurodegeneration , disease , mutation , oncology , alzheimer's disease , pathology , gastroenterology , pediatrics , genetics , biology , presenilin , gene
tau181 begin to decline significantly. Furthermore, this decline is strongly associated with the increased atrophy seen with disease progression. This suggests that measures of CSF tau do not reflect a passive release with neuronal death, but likely represent a more complex process related to the progression of AD pathology. Further, as CSF tau peptides declined with symptom onset and atrophy progression, it is possible that this might reflect the sequestration of soluble tau by the trans-synaptic spreading of insoluble tau tangles.